Microphthalmia-associated transcription factor (MiT) family translocation renal cell carcinoma harbors variable gene fusions involving either TFE3 or TFEB genes. Multiple 5′ fusion partners for TFE3 have been reported, including ASPSCR1, CLTC, DVL2, LUC7L3, KHSRP, PRCC, PARP14, NONO, SFPQ1, MED15, and RBM10. Each of these fusion genes activates TFE3 transcription which can be detected by immunostaining. Using targeted RNA-sequencing, TFE3 fusion gene partners were identified in 5 cases of TFE3 immunohistochemistry positive translocation renal cell carcinoma. Three cases demonstrated known fusions: ASPSCR1-TFE3, MED15-TFE3 and RBM10-TFE3. However, two cases showed unreported NEAT1-TFE3 and KAT6A-TFE3 fusion transcripts. The NEAT1-TFE3 RCC arose in a 59-year-old male; which demonstrated overlapping morphological features seen in NEAT2(MALAT1)-TFEB t(6;11) renal cell carcinoma, including biphasic alveolar/nested tumor cells with eosinophilic cytoplasm. The KAT6A-TFE3 renal cell carcinoma demonstrated typical morphological features of TFE3/Xp11 renal cell carcinoma including papillae, eosinophilic cytoplasm with focal clearing and abundant psammoma bodies. KAT6A gene fusion was reported in some cases of acute myeloid leukemia, which has not been previously reported in solid tumors. This report highlights the genetic complexity of TFE3 translocation renal cell carcinoma; and RNA-sequencing is a powerful approach for elucidating the underlying genetic alterations.
Introduction
Xp11 translocation renal cell carcinoma was renamed as MiT (microphthalmia-associated transcription factor) family translocation renal cell carcinoma in the 2016 World Health Organization classification [1] . This tumor type harbors variable gene fusions involving either TFE3 or TFEB genes [1] . TFE3 is a transcription factor gene located at chromosome band Xp11. 23 . Multiple 5′-fusion partners for TFE3 have been reported, including ASPSCR1, CLTC, DVL2, LUC7L3, KHSRP, PRCC, PARP14, NONO, SFPQ1, MED15, and RBM10 [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] . Each of these fusion genes activates TFE3 transcription, which results in the activation of downstream genes including targets normally activated by MiT family transcription factors (Cathepsin K and melanotic markers) [1, 12, 13] . TEF3/Xp11 renal cell carcinoma generally has papillary architecture, clear cells and psammoma bodies. The tumor cells are often positive for melanocytic markers, and negative or weakly positive for cytokeratins in contrast to classic clear cell and papillary renal cell carcinomas [6, 14] .
Strong nuclear TFE3 stains using an antibody targeting the C-terminal portion of TFE3 is a sensitive and specific marker for Xp11 translocation renal cell carcinoma [15, 16] . However, it is difficult to optimize immunostaining for TFE3, as it is affected by variable fixation conditions. In clinical practice, it is not uncommon to encounter equivocal findings leading to false positive or false negative results. TFE3 break-apart florescence in situ hybridization (FISH) assay has been demonstrated to be more reliable to detect the presence of the translocation [5, 14, 15] . However, some renal cell carcinomas with morphological features of translocation renal cell carcinoma remain negative by immunostaining and FISH studies [5] . With the recent advancement of next-generation sequencing technology, RNA sequencing not only can identify cases not detected by other means, but also can identify various specific translocations in a single assay. In this study, we used targeted RNA-sequencing to identify the fusion genes in five cases of MiT family translocation renal cell carcinoma which had been diagnosed through TFE3 immunohistochemistry and/ or FISH analysis for TFE3 fusions.
Materials and methods

Patients and samples
Five archived cases of renal cell carcinoma with expression of TFE3 by immunohistochemistry were retrieved from the Department of Pathology, Fox Chase Cancer Center (Table 1) . Medical record review provided pertinent clinical information. Adequate tumor sampling for each case had been performed (case 1 (9 sections), case 2 (6 sections), case 3 (12 sections), case 4 (14 sections), case 5 (13 sections)). This study was approved by the Institutional Review Board.
Immunohistochemistry
Immunohistochemistry was performed on 4-μm sections from formalin-fixed, paraffin-embedded (FFPE) tissue using a Ventana Benchmark XT automated stainer (Ventana Medical Systems, Tucson, AZ). The following antibodies were used: Melan-A (monoclonal mouse anti-human antibody, A103; DAKO; 1:100), TFE3 (monoclonal mouse anti-human antibody, MRQ37, Cell Marque; prediluted), PAX8 (monoclonal mouse anti-human antibody, MRQ50, Cell Marque; prediluted), cytokeratin AE1/AE3 (monoclonal mouse anti-human antibody, AE1/AE3, Ventana; prediluted), cytokeratin 7 (monoclonal mouse anti-human antibody, OV-TL 12/30, Dako; 1:800), CAM 5.2 (monoclonal mouse anti-human antibody, BD, 1:100), Cathepsin K (monoclonal mouse anti-human antibody, 3F9, Cell marque, prediluted) and HBM45 (monoclonal mouse antihuman antibody, Dako; 1:60). The corresponding positive and negative controls were shown to be adequate.
RNA-sequencing and data analysis
RNA was isolated from FFPE samples using five 10 μm thick tissue sections. A High Pure FFPE RNA Isolation Kit (Roche, Indianapolis, IN) was used according to the manufacturer's protocol. RNA was quantified using a Nanodrop apparatus and evaluated with an Agilent 2100 bioanalyzer.
Next-generation sequencing-based targeted RNAsequencing analysis was performed using the Illumina TruSight RNA Fusion Panel and a MiniSeq sequencer according to the manufacturer's recommendation (Illumina, San Diego, CA). This targeted RNA fusion panel consists of 507 of the most well-known cancer-related fusion genes (including TFE3), and the gene list is available at www. illumina.com. The Trusight RNA fusion panel covers 7690 exonic regions that are targeted with a total of 21,283 probes.
FISH analysis
FISH/TFE3 analysis for case 1 and 2 were performed at the Hospital of the University of Pennsylvania (Philadelphia, PA) using dual-color DNA break-apart probes (KREATECH Repeat-Free Poseidon TFE3 (Xp11) Break probes, Leica Biosystems). FISH/TFE3 analysis on case 5 was performed at the Mayo Clinic (Rochester, MN) using break-apart probes Xp11.23 (3′TFE3, 5′TFE3) and probe XCEN (DXZ1). FISH for TFEB on case 1 was done at Mayo Clinic (Rochester, MN) using break-apart probes 6p21.1 (3′TFEB, 5′TFEB).
Results
Clinical characteristics
The patients consisted of three females and two males ranging in age from 22 to 73 (mean, 46 years) ( Table 1) . Three patients underwent partial nephrectomies, and two patients had radical nephrectomies. 
Pathological findings
The pathological features are summarized in Table 1 . Three cases demonstrated known fusions: ASPSCR1-TFE3, MED15-TFE3, and RBM10-TFE3. However, case 1 showed a NEAT1-TFE3 fusion gene due to a t(X;11)(p11.23; q13.1). Morphologically, the distinct features observed in this case include abundant psammoma bodies and predominantly alveolar/nested growth pattern as opposed to the papillary architecture observed in the other four cases. This case also demonstrated biphasic tumor cells, i.e., larger epithelioid cells and small lymphocyte-like cells ( Fig. 1a-c) . Distinct basement membrane globules were not identified, as typically found in TFEB/t (6;11) renal cell carcinoma. The large epithelioid cells had eosinophilic cytoplasm with focal clearing (Fig. 1c) , which were only focally positive for cytokeratins, including AE1/3, CAM5.2, and CK7. Melanin pigment was noted focally (Fig. 1c) ; and Melan A immunostaining was focally and weakly positive. These tumor cells were negative for HMB45 and Cathepsin K. Since TFE3 immunohistochemistry was focally positive (Fig. 1d ), FISH analysis with TFE3 (Xp11) break-apart probes was performed, and this study confirmed the presence of a TFE3 translocation. FISH for TFEB translocation was negative.
Another case had a KAT6A-TFE3 fusion gene due to a t (X;8)(p11.23; p11.21). This tumor featured typical TFE3/ Xp11 morphology including papillae and abundant psammoma bodies. The tumor cells had eosinophilic cytoplasm with focal clearing (Fig. 2a, b) . The tumor cells were positive for CAM5.2, and only focally positive for AE1/3, CK7 and Melan A. Similar to the NEAT1-TFE3 renal cell carcinoma, the TFE3 immunohistochemistry was only focally positive. FISH analysis with TFE3 (Xp11) break-apart probes was positive for a TFE3 translocation (Fig. 2c) .
Interestingly, the RBM10-TFE3 renal cell carcinoma (case 4, Fig. 2e , f) also showed biphasic tumor cells without basement membrane globules. However, unlike NEAT1-TFE3 renal cell carcinoma, the RBM10-TFE3 renal cell carcinoma did not feature eosinophilic cytoplasm. These tumor cells were positive for Melan A and Cathepsin K, negative for AE1/3, CAM5.2, CK7, and PAX8. The ASPSCR1-TFE3 renal cell carcinoma (case 2) case had typical TFE3/Xp11 morphology including papillae with clear cytoplasm and abundant psammoma bodies. The MED15-TFE3 renal cell carcinoma (case 3, Fig. 2d ) showed papillae and granular cytoplasm with clearing; however, no psammoma bodies were identified. The tumor cells were focally positive for CAM5.2, Cathepsin K and Melan A, 
Discussion
Xp11 translocation renal cell carcinoma was first recognized as a specific category of renal cell carcinoma in the 2004 WHO classification [17] . In 2016, This group of renal cell carcinoma was renamed MiT family translocation renal cell carcinoma in the new World Health Organization classification [1] . This tumor type harbors variable gene fusions involving either TFE3 or TFEB genes [1] . The first fusion/translocation was cloned in 1996, which was found to fuse the TFE3 transcription factor gene on Xp11.2 to the PRCC gene located at 1q21.2 [18, 19] . Since that time, other various TFE3 fusion gene partners have been described, including ASPSCR1, CLTC, DVL2, LUC7L3, KHSRP, PARP14, NONO, SFPQ1, MED15, and RBM10 [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] .
The predominant histological pattern of TFE3/Xp11 renal cell carcinoma is papillary architecture with clear cells and psammoma bodies. The tumor cells are frequently positive for melanocytic markers with negative or low expression of cytokeratins, which distinguishes them from other renal cell carcinoma subtypes [6, 14] . Renal cell carcinomas with MALAT1 (Alpha)-TFEB /t(6;11) are biphasic neoplasms composed of nested larger epithelioid cells with eosinophilic and vacuolated/clear cytoplasm and smaller cells surrounding basement membrane material [1, 20, 21] . The NEAT1-TFE3 renal cell carcinoma case reported here demonstrated a similar phenotype with an alveolar/nested growth pattern and only focal papillary architecture. The cytoplasm showed eosinophilic appearance with clearing. Our example lacks basement membrane material [21] . Interestingly, the MALAT1(metastasis-associated lung adenocarcinoma transcript 1) is also known as NEAT2 (nuclear-enriched abundant transcript 2) [22] .
The Nuclear Enriched Abundant Transcript 1 (NEAT1) gene, located at 11q13.1, produces a long non-coding RNA (lncRNA), a class of intergenic non-coding RNAs longer than 200 nucleotides that can regulate specific gene expression at multiple steps. NEAT1 is a lncRNA localizing to a nuclear structure called paraspeckles [23] . NEAT1 is aberrantly up-regulated in various types of cancer including carcinomas of the ovary, colon and genitourinary system [24] [25] [26] . NEAT1 has been shown to be overexpressed in clear cell renal cell carcinoma, and upregulation of NEAT1 was positively correlated with tumor size, higher Fuhrman grade, and lymph node metastasis [26] . Interestingly, NEAT1 is involved in organizing a paraspeckle protein known as NONO (Non-POU domain-containing octamerbinding protein), which is one of the TFE3 fusion gene partners [6, 8, 27] . Similar to NEAT1, the TFEB/t(6;11) fusion partner MALAT1/NEAT2 is a lncRNA; and the fusion of NEAT2 and TFEB results in overexpression of TFEB [1, 21, 22, 28] . Although the NEAT2 promoter drives expression of the NEAT2-TEFB fusion gene, the NEAT2 gene does not contribute to the open reading frame [28, 29] .
Except for the NEAT1-TFE3 renal cell carcinoma, the other four Xp11 renal cell carcinoma cases reported here had predominantly papillary architecture, cytoplasmic clearing and low/negative cytokeratin expression; and three of four cases were positive for Melan A. Two cases had psammoma bodies (Tables 1, 2 ). The KAT6A-TFE3 renal cell carcinoma case demonstrated typical morphological features of TFE3/ Xp11 renal cell carcinoma including papillae and abundant psammoma bodies. In addition, the tumor cells had eosinophilic cytoplasm with focal clearing. Lysine acetyltransferase 6A (KAT6A) belongs to the histone acetyltransferase (HAT) family, which was reported to fuse to CREB-binding protein (CBP) in some cases of acute myeloid leukemia [30] [31] [32] . These proteins have histone acetyltransferase activity and are involved in transcriptional regulation and cell cycle control [33, 34] . Notably, gene fusions involving KAT6A have not been previously reported in solid tumors.
Only ten cases of RBM10-TFE3 renal cell carcinoma have been reported. These cases can have sheets of small cells with "pseudo-rosette-like" architectures, mimicking the typical morphology of TFEB/t(6;11) renal cell carcinoma [5, 7] . The RBM10-TFE3 renal cell carcinoma case reported here not only was completely negative for AE1/3, CAM5.2, and CK7, it also did not express PAX8. However, it was positive for Melan A and Cathepsin K. This tumor might belong to melanotic Xp11 translocation renal cell carcinoma/perivascular epithelioid cell neoplasms, which can be keratin(-)PAX8(-)Cathepsin K(+) Melan A(+), although the most reported melanotic Xp11 translocation renal cell carcinoma/perivascular epithelioid cell neoplasms had SFPQ-TFE3 fusion. It may contain variable amounts of finely brown melanin pigment which was not identified in this case [6, 35, 36] . It should be mentioned that both TFE3 and RBM10 are located on the same chromosome sub-band (Xp11.23), only 1.82 Mb apart, so a rearrangement involving these two genes is very unlikely to be detected by conventional FISH analysis [5] .
As noted by Argani et al., it is difficult to optimize TFE3 immunostaining due to variable fixation conditions [5, 16] . In our study, three of five cases only had focal or weak positivity for TFE3 staining. Therefore, one should interpret TFE3 immunostaining cautiously. Furthermore, even the use of FISH testing with break-apart probes can sometimes be problematic, as it may be difficult or impossible to detect an inversion or translocation of chromosome X, such as NONO-TFE3 and RBM10-TFE3 rearrangements [5] [6] [7] 37] . Thus, RNA-sequencing or targeted multiplex RT-PCR would be a better option for identifying such cases [37] .
Conclusion
In this study, two new members of MiT family translocation renal cell carcinoma, NEAT1-TFE3 and KAT6A-TFE3 renal 
